Navigation Links
Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
Date:5/14/2008

Recognized clinical trial innovations advocate to lead expansion of Cytel's

adaptive trial design and implementation business

CAMBRIDGE, Mass., May 14 /PRNewswire/ -- Cytel Inc., a leading provider of clinical trial design services and specialized statistical software, today announced the appointment of Judith Quinlan as Vice President, Adaptive Trials.

Judith Quinlan brings over twenty years of statistical experience to the Cytel team. Prior to joining Cytel Judith spent 10 years with GSK, most recently as Statistics Director for biopharmaceuticals, and previously as Statistics Director for Neurology and GI. Throughout the last seven years she's focused on bridging the gap between new clinical research concepts and the challenging practicalities of conducting complex trials.

"Judith Quinlan has been a persistent and persuasive proponent of adaptive clinical trials both at GSK, and through her work with the PhRMA Working Group on Adaptive Designs (ADWG). This is helping pave the way toward the wide acceptance of innovative, flexible clinical study approaches. Judith combines clinical theory and practice with a strategic business perspective on Clinical Development Programs. We are very pleased, indeed, to have Judith on board," said Cytel's CEO, Ranganath Nayak.

In her new role, Judith Quinlan will guide Cytel's adaptive trial design and implementation offerings, leveraging her previous successes in managing cross-functional clinical research teams to drive more productive planning and implementation of early stage and confirmatory trials. In addition to overseeing Cytel's flourishing adaptive study efforts, Judith will continue her advocacy and education work as an active member of the PhRMA Working Group on Adaptive Designs.

A popular speaker on adaptive trial design and operations, Judith Quinlan has co-authored articles on numerous clinical research-related topics. Judith has published in such prestigious journals as Pharmacotherapy and Computational Statistics, and she co-authored with Wyeth's Mike Krams the influential PhRMA group's paper on "Implementing Adaptive Designs: Logistical and Operational Issues."

About Cytel

Cytel Inc. is a leading provider of clinical trial design services and specialized statistical software for the biopharmaceutical, medical device, academic, and government research markets. Cytel's East(R) system is used by biostatisticians and clinicians at hundreds of companies, throughout academia and by regulators to design, simulate and monitor group sequential and adaptive clinical trials. Cytel provides trial sponsors with innovative tools, training, and consultation to increase process efficiencies and reduce development costs.


'/>"/>
SOURCE Cytel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
2. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
3. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
4. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
5. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
6. Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
9. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
10. Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the ... Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market ... Low drug registration cost in Latin American countries and ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... 19, 2017  IRIDEX Corporation (Nasdaq: IRIX ... for the first quarter 2017 after the close of ... team will host a corresponding conference call beginning at ... Investors interested in listening to the conference call may ... or (703) 326-3030 for international callers, using conference ID: ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Journal of Oral Implantology ... have severe consequences to overall dental health, including complications with speech, eating, and overcompensation ... dental implants to replace lost teeth. As the number of tooth replacements increase, it ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... Hackensack, N.J. has been honored by Enterprising Women magazine as one of its ... world’s top women business owners. Winners have demonstrated that they have fast-growth businesses, ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... RawTrition now ... easy way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients ... the cellular level because the body recognizes its raw form (unlike the synthetically made ...
(Date:4/26/2017)... ... 26, 2017 , ... MYOLYN, a medical technology company dedicated ... received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two ... devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and ... its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne ...
Breaking Medicine News(10 mins):